Illinois Municipal Retirement Fund Raises Holdings in Option Care Health, Inc. $OPCH

Illinois Municipal Retirement Fund lifted its position in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 48.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 123,574 shares of the company’s stock after purchasing an additional 40,358 shares during the period. Illinois Municipal Retirement Fund owned about 0.08% of Option Care Health worth $3,430,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Cornerstone Planning Group LLC raised its stake in shares of Option Care Health by 7,621.4% during the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after purchasing an additional 1,067 shares during the last quarter. McIlrath & Eck LLC purchased a new position in Option Care Health in the 2nd quarter valued at $37,000. Elevation Point Wealth Partners LLC acquired a new position in Option Care Health in the 2nd quarter valued at $40,000. EverSource Wealth Advisors LLC raised its position in Option Care Health by 528.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,407 shares of the company’s stock worth $46,000 after buying an additional 1,183 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its position in Option Care Health by 987.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,414 shares of the company’s stock worth $39,000 after buying an additional 1,284 shares during the last quarter. 98.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on OPCH shares. Deutsche Bank Aktiengesellschaft increased their price objective on Option Care Health from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Morgan Stanley upped their price target on shares of Option Care Health from $35.00 to $38.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 13th. Citizens Jmp reiterated a “market outperform” rating and issued a $38.00 price target (up previously from $36.00) on shares of Option Care Health in a report on Tuesday, January 13th. Citigroup reissued an “outperform” rating on shares of Option Care Health in a report on Tuesday, January 13th. Finally, Jefferies Financial Group restated a “buy” rating and set a $37.00 target price on shares of Option Care Health in a research report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.46.

Option Care Health Stock Up 2.9%

Shares of NASDAQ OPCH opened at $35.42 on Friday. The firm’s 50-day moving average is $33.61 and its two-hundred day moving average is $30.17. The company has a market capitalization of $5.62 billion, a PE ratio of 28.11, a price-to-earnings-growth ratio of 2.11 and a beta of 0.84. Option Care Health, Inc. has a 12-month low of $24.24 and a 12-month high of $36.80. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.56 and a quick ratio of 1.05.

Option Care Health Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.